Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer

October 11, 2019 5:00 pm

By Wayne Kuznar

The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more

‘Wild Idea’ Opens Possible New Frontier for Preventing Ovarian Cancer

October 9, 2019 3:00 pm

A laboratory study published in Clinical Cancer Research offers a new hypothesis about how ovarian cancer forms and suggests how it might be prevented.

The study is the first to show that the natural stiffening of the ovaries called fibrosis … Read more

How Has Cancer Changed the Way Patients Live Their Lives?

October 5, 2019 5:00 pm

We would love to hear from the Clearity Community – patients, caregivers, and loved ones – about your experiences on how you have been affected by ovarian cancer. Sharing your story is a way to promote awareness, connect with people Read more

Ovarian Cancer Drug Misses Mark… Right?

October 1, 2019 5:00 pm

By Charles Bankhead

Anti-folate fails phase III test, but key biomarker measurement may have been faulty.

An antibody-drug conjugate (ADC) targeting folate-receptor expression failed to improve progression-free survival (PFS) versus chemotherapy in patients with recurrent platinum-resistant ovarian cancer, according to … Read more

Trametinib Tx Shows Promise in Tough-to-Treat LGSOC

September 30, 2019 6:00 pm

By Pam Harrison

Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.

Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more

PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Cancer?

September 29, 2019 6:00 pm

By Ed Susman

PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines.

Patients with newly diagnosed advanced ovarian cancer who responded to first-line chemotherapy, then were treated with niraparib (Zejula), had a significantly reduced risk … Read more

First-Line Combo Boosts PFS in Advanced Ovarian Cancer

September 28, 2019 5:00 pm

By Charles Bankhead

Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup.

Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab, a … Read more

Can Recurrent Ovarian Cancer Patients Avoid Chemotherapy?

September 20, 2019 8:00 pm

By Dave Levitan

The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more

UCSD Researchers Find FAK Protein Linked to Chemotherapy Resistance in Ovarian Cancer

September 12, 2019 5:00 pm

Although the number of women being diagnosed and dying of ovarian cancer is declining, recurrence, drug resistance, and mortality remains high for women with high-grade serous ovarian carcinoma, the most common form of epithelial ovarian cancer. 

A new study in Read more

Steps Through OC: Early Findings From a National Pilot Delivering Virtual, Individualized Psychosocial Support to Ovarian Cancer Survivors and Caregivers

September 8, 2019 5:00 pm

By Thomas J. Pier, MSW, LCSW, OSW-C, CMF, and Marina Baroff, MPH, MA, FACHE

What if every woman with ovarian cancer had help setting a clear direction through the uncertain landscape of the diagnosis? Imagine these women having access to … Read more

Rare Ovarian Cancer Confirmed as Not Seeded from Elsewhere

September 6, 2019 5:15 pm

By Peter MacCallum

An international study led by Peter Mac has revealed the origin of mucinous ovarian cancer (MOC) confirming, unlike other types of ovarian cancer, this rare cancer is not seeded from elsewhere in the body.

The research provides … Read more

An Introduction to Ovarian Cancer Awareness Month 2019

September 1, 2019 8:00 am

By Dr. Laura Shawver, Founder of The Clearity Foundation

Whenever I talk with someone who just received an ovarian cancer diagnosis, it brings back the feelings that I had when I heard the words, “you have ovarian cancer.” I can … Read more

Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?

August 26, 2019 7:00 pm

By Dave Levitan

The combination of a poly (ADP-ribose) polymerase (PARP) inhibitor and immune checkpoint inhibition with tislelizumab was well tolerated and showed promising anti-tumor activity in a phase I trial of patients with multiple solid tumor types, according to … Read more

Researchers Develop Early Detection Test for Ovarian Cancer

August 23, 2019 5:00 pm

Researchers from Queen’s University Belfast have developed a test that may be able to detect ovarian cancer up to two years earlier than current approaches.

The researchers discovered that the presence of four proteins together, known as a biomarker panel, … Read more

I’m Addicted to Anxiety: Facing Cancer Fears Head-on

August 14, 2019 6:00 pm

This article discusses the anxiety that often surrounds a cancer diagnosis and the importance of seeking professional help. Steps Through OC offers free, professional ovarian cancer counseling for women, families and caregivers coping with ovarian cancer. Our goal is to Read more

AstraZeneca’s Ovarian Cancer Drug Hits Main Goal in New Study

August 13, 2019 5:15 am

By John Lauerman

AstraZeneca Plc’s Lynparza got a boost from results of a study that may widen the drug’s use among patients with advanced ovarian cancer.

Ovarian tumor growth slowed in patients who got Lynparza in addition to a … Read more

Ovarian Cancer: Is this the Beginning of the End?

August 10, 2019 6:00 pm

By Michael J. Birrer, MD, PhD

There will be 22,530 new cases of ovarian cancer in the United States this year.

Although tumors often present at an advanced stage, it remains one of the most chemosensitive epithelial cancers, with a … Read more

BRCA Mutation, Preventive Surgery, and Osteoporosis

August 8, 2019 4:00 pm

By Kristen Monaco

Researchers advocate for increased hormone therapy for high-risk women.

Bone health suffered in women with a BRCA mutation who underwent preventive oophorectomy, Canadian researchers reported.

Premenopausal women with the BRCA1 or BRCA2 mutation experienced a significant decline … Read more

My Survival Garden: Overcoming Ovarian Cancer

August 5, 2019 6:00 pm

By Sherry B. Hanson

While recovering from ovarian cancer and chemotherapy, I got it into my head that I needed a garden space. My garden represents not only my physical labor, but also my focus, which is on the future.Read more

Germline BRCA2 Mutations Linked to Pediatric Lymphomas

August 2, 2019 5:00 pm

By Leah Lawrence

In addition to putting carriers at increased risk for breast and ovarian cancers, BRCA2 germline mutations carriers are also at increased risk for pediatric and adolescent non-Hodgkin lymphoma (NHL), according to data from the SJLIFE study.… Read more